Exscientia Ai Ltd., A Wholly Owned Subsidiary Of Recursion Pharmaceuticals, Inc.
Clinical trials sponsored by Exscientia Ai Ltd., A Wholly Owned Subsidiary Of Recursion Pharmaceuticals, Inc., explained in plain language.
-
AI-Designed drug trial seeks to shrink tough cancers
Disease control Recruiting nowThis study is testing a new drug called GTAEXS617 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors in cancers like head & neck, lung, pancreatic, ovarian, and bre…
Phase: PHASE1, PHASE2 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
AI-Designed pill enters human testing for tough blood cancers
Disease control Recruiting nowThis is the first human study of an experimental oral drug called EXS73565 for people with advanced B-cell blood cancers that have returned or stopped responding to standard treatments. The main goal is to find a safe dose and understand how the drug behaves in the body, while al…
Phase: PHASE1 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC